Antidiabetic medications that improve glycemic control as well as cardiovascular outcomes will be the mainstay of treatment for type 2 diabetes moving forward. This article reviews the beneficial effects of the thiazolidinedione pio-glitazone of ameliorating hyperglycemia and improving cardiovascular risk factors. While the newer sodium–glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist drug classes have confirmed cardiovascular benefits, pioglitazone also has been shown to reduce major adverse cardiovascular events, in both people with type 2 diabetes and nondiabetic subjects with insulin resistance. Adverse effects associated with pioglitazone can be miti-gated by its use at a lower dose and in combination with antidiabetic agents from other drug classes.
|Idioma original||English (US)|
|Número de páginas||5|
|Estado||Published - ago 2021|
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism